An interventional study of Glycan in Crohn Disease (CD), sponsored by GLSMED Learning Health S.A.. Recruiting at 1 site in Portugal. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by GLSMED Learning Health S.A. · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Crohn Disease with a site in Portugal — 16 open to participants now, 23 under way, 15 of them phase 3. Crohn Disease · Portugal.
Among the 53 studies in Crohn Disease with a site in Portugal, this one is the 44th largest by planned enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2025, is one of 2 with no phase, reaches primary completion later than 9 of the 22 other live ones, and was the 48th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →16 of the 53 studies in Crohn Disease with a site in Portugal are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Portugal, United States, Argentina and 27 more countries
Ages 18+
GLSMED Learning Health S.A. · Sites in Portugal, Italy, Netherlands and 3 more countries
Ages 16–35 · Healthy volunteers
Janssen Research & Development, LLC · Sites in Portugal, United States, Argentina and 25 more countries
Ages 18+
Hoffmann-La Roche · Sites in Portugal, United States, Argentina and 24 more countries
Ages 16–80
Hoffmann-La Roche · Sites in Portugal, United States, Argentina and 35 more countries
Ages 16–80
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 36 · Phase 4 1
First in 2005; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 500 across the 45 interventional studies, 928 across the 8 observational. Of the 29 that completed or were terminated, 27 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 53 have an industry lead sponsor. The 10 most frequent:
GLSMED Learning Health S.A. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
GLSMED Learning Health S.A. has 3 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Crohn Disease with a site in Portugal that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 53 studies in Crohn Disease with a site in Portugal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The overall aim of this proof-of-concept trial is to investigate the effect of an orally administered glycan on the modulation of the dysregulation of host-microbiome interactions and its effect on the mucosal immune response. Post-operative Crohn's Disease patients will be used as a representative model to mimic the immunopathogenic pathway of health-to-disease transition. Changes in gut glycocalyx seem to be a primary event involved in the disruption of the interaction between the microbiota and the host immune system. Thus, this study aims to assess the effect of the modulation of the glycome on the microbial and immunological changes that contribute to disease development.
Inclusion Criteria
Exclusion Criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Glycan
The post-operative CD patients will receive an orally administered glycan.
The effect of the modulation of the glycome on the microbial changes that contribute to disease development
Time frame: From enrolment until 6 months following surgery
The effect of the modulation of the glycome on the immunological changes that contribute to disease development
Time frame: From enrolment until 6 months following surgery
The immunomodulatory effect of glycans on endoscopic recurrence
Time frame: From enrolment until 6 months following surgery
The immunomodulatory effect of glycans on clinical recurrence
Time frame: From enrolment until 6 months following surgery
The immunomodulatory effect of glycans on histological recurrence
Time frame: From enrolment until 6 months following surgery
The immunomodulatory effect of glycans on systemic inflammatory biomarkers pre-surgery
Time frame: From enrolment until 6 months following surgery
The immunomodulatory effect of glycans on systemic inflammatory biomarkers post-surgery
Time frame: From enrolment until 6 months following surgery
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.
Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 36 months is below that.
Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GLSMED Learning Health S.A.